07/2013 - Državni zavod za intelektualno vlasništvo
12.07.2015 • Views
Share Embed Flag

07/2013 - Državni zavod za intelektualno vlasništvo

07/2013 - Državni zavod za intelektualno vlasništvo

07/2013 - Državni zavod za intelektualno vlasništvo

SHOW MORE
SHOW LESS
ePAPER READ
DOWNLOAD ePAPER
dziv.hr

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

START NOW

2240 HR - Patenti - Hrvatski glasnik <strong>intelektualno</strong>g vlasništva 20, <strong>2013</strong>, 7, 2169 – 2293(31) 200416 (32) 09.08.2005. (33) US(54) UPOTREBA PEPTIDA KOJI SE VEŽU ZA TPO RECEPTORUSE OF PEPTIDES THAT BIND TO TPO RECEPTOR(73) Ortho-McNeil Pharmaceutical, Inc., US Route 202 South, Raritan,NJ 08869, US(72) Brian R. Macdonald, 19 Paper Mill Road, 19<strong>07</strong>3 Newtown Square,PA, USJeffery Kenneth Weis, 106 South Honeyman Road, 08889Whitehouse Station, NJ, USEdward John Yurkow, 123 Woods Road, 08844 Hillsborough, NJ,US(74) Odvjetničko društvo Vukmir i suradnici, Zagreb, HR(57) Terapeutski efektivna do<strong>za</strong> peptidnog spoja koji sadrži sljedećusekvencu: (H-IEGPTLRQ(2-Nal)LAARX 10 )-K(NH 2 )-(X 10 RAAL(2-Nal)QRLTPGEI)-H, (Identifikacijski broj sekvence: 7), naznačen time daX 10 je sarkozin <strong>za</strong> upotrebu u tretiranju hematoloških poremećaja kodljudi, naznačen time da se spomenuti peptidni spoj primjenjuje u opsegudo<strong>za</strong> između 0.1 i 0.75 µg/kg.Patent sadrži još 29 patentnih <strong>za</strong>htjeva.(51) MKP (10) HR P<strong>2013</strong>0549 T1C<strong>07</strong>C 229/42 (2006.01)A61K 31/136 (2006.01)A61P 35/00 (2006.01)(11) P<strong>2013</strong>0549 (46) 31.<strong>07</strong>.<strong>2013</strong>.(21) P<strong>2013</strong>0549T (22) 17.06.<strong>2013</strong>.(86) PCT/IE2006000<strong>07</strong>8 24.<strong>07</strong>.2006.(96) EP 06766085.2 24.<strong>07</strong>.2006.(87) WO20<strong>07</strong>010516, 25.01.20<strong>07</strong>.(97) EP 1910270, 16.04.2008. 200816, En(97) EP 1910270, 08.05.<strong>2013</strong>. <strong>2013</strong>19, En(31) RM20050389 (32) 22.<strong>07</strong>.2005. (33) IT(54) SPOJEVI I NJIHOVE SOLI SPECIFIČNI ZA PPAR RECEPTORE IEGF RECEPTORE TE NJIHOVA PRIMJENA U PODRUČJUMEDICINECOMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPARRECEPTORS AND THE EGF RECEPTORS AND THEIR USE INTHE MEDICAL FIELD(73) Nogra Pharma Limited, 33 Sir John Rogerson's Quay, Dublin 2, IE(72) Giancarlo Naccari, Via Bellinzona, 7, 20052 Mon<strong>za</strong>, ITSergio Baroni, Via Piazzolo 3, 24030 Villa D'Adda, IT(74) ZMP IP d.o.o., Zagreb, HR(57) Spoj i njegove soli, i<strong>za</strong>bran iz grupe koja obuhvaća:(73) Aventis Pharma S.A., 20, avenue Raymond Aron, 92160 Antony,FR(72) Eric Didier, 100 boulevard Auguste Blanqui, 75013 Paris, FRMarc-Antoine Perrin, 18 rue Raoul Allavoine, 78350 Jouy en Josas,FR(74) Hraste & Partneri odvjetničko društvo, Zagreb, HR(57) Acetonski solvat, naznačen time što je solvat 4-acetoksi-2α-benzoiloksi-5ß,20-epoksi-1-hidroksi-7ß,10ß-dimetoksi-9-oksotaks-11-en-13α-il-(2R,3S)-3-terc-butoksikarbonilamino-2-hidroksi-3-fenilpropionata.Patent sadrži još 9 patentnih <strong>za</strong>htjeva.(51) MKP (10) HR P<strong>2013</strong>0405 T1C<strong>07</strong>D 405/04 (2006.01)C<strong>07</strong>D 235/12 (2006.01)A61K 31/4184 (2006.01)A61P 5/00 (2006.01)(11) P<strong>2013</strong>0405 (46) 31.<strong>07</strong>.<strong>2013</strong>.(21) P<strong>2013</strong>0405T (22) 08.05.<strong>2013</strong>.(86) PCT/US20<strong>07</strong>060883 23.01.20<strong>07</strong>.(96) EP <strong>07</strong>717362.3 23.01.20<strong>07</strong>.(87) WO20<strong>07</strong>087518, 02.08.20<strong>07</strong>.(97) EP 1984343, 29.10.2008. 200844, En(97) EP 1984343, 27.02.<strong>2013</strong>. <strong>2013</strong>09, En(31) 761548 P (32) 24.01.2006. (33) US(54) 2-SUPSTITUIRANI BENZIMIDAZOLI KAO SELEKTIVNIMODULATORI ANDROGENIH RECEPTORA2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVEANDROGEN RECEPTOR MODULATORS (SARMS)(73) Janssen Pharmaceutica N.V., Turnhoutseweg 30, 2340 Beerse, BE(72) Alford C. Vernon Jr., Johnson & Johnson PharmaceuticalResearch&Develop, Welsh & McKean Roads, P.O. Box 776, 19477Spring House, PA, USJames C. Lanter, Johnson & Johnson PharmaceuticalResearch&Develop., 665 Stockton Drive, 19341 Exton, PA, USRaymond A. Ng, AtheroGenics, Inc., 8995 Westside Parkway,30004 Alpharetta, GA, USZhihua Sui, c/o Johnson & Johnson Pharmaceutical R&D, LLC, 665Stockton Drive, 19341 Exton, PA, US(74) Odvjetničko društvo Vukmir i suradnici, Zagreb, HR(57) Spoj formule (I)naznačen time daR 1 je vodik;R 2 i R 3 su svaki klor;R 4 je i<strong>za</strong>bran iz grupe koja se sastoji od izopropenil, Z-2-propen-3-il i (-*-)-vinil;R 5 je OH;Alternativno, R 4 i R 5 su uzeti <strong>za</strong>jedno s atomom na koji su ve<strong>za</strong>ni daformiraju 2- [1,3] dioksolanil;ili njihovu farmaceutski prihvatljivu sol.Patent sadrži još 6 patentnih <strong>za</strong>htjeva.iPatent sadrži još 10 patentnih <strong>za</strong>htjeva.(51) MKP (10) HR P<strong>2013</strong>0322 T1C<strong>07</strong>D 305/14 (2006.01)A61K 31/335 (2006.01)(11) P<strong>2013</strong>0322 (46) 31.<strong>07</strong>.<strong>2013</strong>.(21) P<strong>2013</strong>0322T (22) 10.04.<strong>2013</strong>.(86) PCT/FR2004002344 16.09.2004.(96) EP 04787385.6 16.09.2004.(87) WO2005028462, 31.03.2005.(97) EP 1667986, 14.06.2006. 200624, Fr(97) EP 1667986, 16.01.<strong>2013</strong>. <strong>2013</strong>03, Fr(31) 0311016 (32) 19.09.2003. (33) FR(54) ACETONSKI SOLVAT DIMETOKSIDOCETAKSELA I POSTUPAKNJEGOVE PRIPRAVEDIMETHOXY DOCETAXEL ACETONE SOLVATE ET METHODFOR THE PREPARATION THEREOF(51) MKP (10) HR P<strong>2013</strong>0602 T1C<strong>07</strong>D 413/14 (2006.01)(11) P<strong>2013</strong>0602 (46) 31.<strong>07</strong>.<strong>2013</strong>.(21) P<strong>2013</strong>0602T (22) 01.<strong>07</strong>.<strong>2013</strong>.(86) PCT/US2004024716 30.<strong>07</strong>.2004.(96) EP 04786150.5 30.<strong>07</strong>.2004.(87) WO2005016893, 24.02.2005.(97) EP 1656372, 17.05.2006. 200620, En(97) EP 1656372, 10.04.<strong>2013</strong>. <strong>2013</strong>15, En(31) 491641 P (32) 30.<strong>07</strong>.2003. (33) US531598 P 19.12.2003. US572246 P 18.05.2004. US(54) SPOJEVI 2,4-PIRIMIDINDIAMINA ZA UPORABU KODLIJEČENJA ILI SPREČAVANJA AUTOIMUNIH BOLESTI2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR USE IN THETREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES(73) Rigel Pharmaceuticals, Inc., 1180 Veterans Boulevard, South SanFrancisco, CA 94080, US(72) Singh Rajinder, 832 Hillman Avenue, 94002 Belmont, CA, USISSN 1847-3024

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!